Comparative Pharmacology
Head-to-head clinical analysis: BRINZOLAMIDE versus METHAZOLAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINZOLAMIDE versus METHAZOLAMIDE.
BRINZOLAMIDE vs METHAZOLAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
1 drop of 1% solution in the affected eye(s) twice daily.
Oral: 50-100 mg two to three times daily.
MODERATE Risk
MODERATE Risk
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Clinical Note
moderateMethazolamide + Etacrynic acid
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid."
Clinical Note
moderateMethazolamide + Bumetanide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Bumetanide."
Clinical Note
moderateMethazolamide + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Hydrochlorothiazide."
Clinical Note
moderateTerminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Category A/B
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Methazolamide + Indapamide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Indapamide."